Freenome (FRNM) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

$1.10

Estimate

-$0.19

Surprise

+666.1%

Score today

5.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Freenome (FRNM) beat the -$0.19 estimate with adjusted EPS of $1.10 — a large 666.1% upside surprise.

• Freenome Q3 2026 Earnings Call Transcript — benzinga, 2026-11-10
• Freenome Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-10
• UPDATE: Freenome Q3 Adj. EPS $1.10 Beats $0.41 Estimate, Sales $183.489M Beat $105.866M Estimate — benzinga, 2026-11-10

TrendMatrix currently rates FRNM Sell at 5.9/10; no pre/post engine snapshot brackets this report.

1 of the last 1 quarters beat the estimate; this quarter's +666.1% surprise compares with a +666.1% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$11.56

Price target

$15.66

Stop

$10.75

Upside to target

+35.5%

Reward-to-risk

2.4:1

Model outputs from TrendMatrix’s engine as of 2026-11-12 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Diagnostics & Research

Market cap

$1.24B

P/E (fwd)

-4.8

52-week range

$9.71–$17.50

Off 52-week high

33.9%

RSI (14)

37

Volume vs avg

1.36×

Score today

5.9/10